Researchers have discovered that after weight loss, individuals with overweight and obesity show increased levels of Kallistatin in their subcutaneous white adipose tissue, a protein linked to improved metabolism and potential therapeutic benefits for obesity and type 2 diabetes. This finding, explored through both clinical and animal studies, highlights Kallistatin’s role in enhancing hepatic insulin sensitivity, suggesting it as a promising target for future treatments.
New research indicates that weight loss in overweight individuals boosts Kallistatin expression in fat tissue, enhancing metabolism and presenting a new target for treating obesity and type 2 diabetes. After losing weight, individuals who were overweight or obese exhibited increased levels of the protein Kallistatin in their subcutaneous white adipose tissue, according to a recent study by researchers at the DZD. Moreover, Kallistatin has been shown to enhance metabolism, potentially paving the way for new treatments for obesity and type 2 diabetes. The findings were recently published in the journalAn increasing number of people are developing type 2 diabetes and obesity.
Among other things, it is involved in counteracting inflammation and healing wounds.
Reference: “Role of human Kallistatin in glucose and energy homeostasis in mice” by Leontine Sandforth, Sebastian Brachs, Julia Reinke, Diana Willmes, Gencer Sancar, Judith Seigner, David Juarez-Lopez, Arvid Sandforth, Jeffrey D. McBride, Jian-Xing Ma, Sven Haufe, Jens Jordan and Andreas L. Birkenfeld, 29 February 2024,SciTechDaily: Home of the best science and technology news since 1998. Keep up with the latest scitech news via email or social media.